The Forgotten Search for an LSD “Antidote”
This commentary reconstructs a neglected early clinical finding in psychopharmacology: The mid-1950s clinical observation that chlorpromazine partially antagonizes the subjective effects of Lysergic acid diethylamide (LSD). Here, we provide the first English translation of the foundational 1955 study by Giberti and Gregoretti. This early work, alongside some contemporaneous and ethically abusive human experimentation funded by the Central Intelligence Agency of the federal government of the United States (CIA) under its MKULTRA program, demonstrated significant pharmacological blockade. However, this line of inquiry was severed from the scientific literature following the suppression of psychedelic research in the 1970s. Consequently, this clear drug–drug interaction remained an isolated clinical fact without a mechanistic explanation for decades. Modern neuropharmacology has now elucidated the precise receptor-level basis: Chlorpromazine acts as an antagonist at the 5-HT 2A receptor, the primary molecular target of classic psychedelics like LSD. Thus, contemporary receptor knowledge validates and explains these prescient, premechanistic clinical insights.
Authors
- Roberto De Filippo (ORCID: https://orcid.org/0000-0002-4085-9114)
Institutions
- Allen Institute (US)
- Bernstein Center for Computational Neuroscience Berlin (DE)
Publication Details
- Journal
- Psychedelic Medicine
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1177/28314425261507297
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00